| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Sertaconazole Nitrate targets fungal cytochrome P-450 sterol C-14 alpha-demethylase (lanosterol 14α-demethylase), an enzyme essential for converting lanosterol to ergosterol. It also acts as a microtubule inhibitor in mammalian cells.
|
|---|---|
| ln Vitro |
Sertaconazole nitrate (0.03-40 µg/mL; 24 hours) inhibits 150 yeast strains, with an arithmetic mean MIC of 0.77 µg/mL, including six species of Candida [1]. Sertaconazole nitrate (1 µg/mL; 5, 10, 30, 60 minutes) has a time-dependent effect on p38 MAP kinase activation [2]. Dependent on p38 activation, sertaconazole nitrate (1, 2 µg/mL; 6, 8, or 24 hours) doubles PGE2 release via COX-2 in keratinocytes [2]. By depolymerizing interphase and spindle microtubules, sertaconazole nitrate (10, 20, 30, 40 µM; 24 h) promotes a significant mitotic arrest, resulting in chromosomal aggregation abnormalities and anti-proliferative effects [3]. Using the p53 pathway, sertaconazole nitrate (20, 40 µM; 24 hours) causes apoptosis in HeLa cells [3]. HeLa cell migration is inhibited by sertaconazole nitrate (20, 30 µM; 24, 48, and 72 hours) in a concentration-dependent manner [3]. In A549 and H460 cells, sertaconazole nitrate (15, 30 µM; 24 hours) can cause autophagy [4].
In vitro, Sertaconazole Nitrate exhibits broad-spectrum antifungal activity by inhibiting ergosterol synthesis, leading to increased cellular permeability and leakage. It also demonstrates antiproliferative activity against cancer cells by inducing mitotic arrest through microtubule depolymerization, and induces apoptosis and autophagy while inhibiting cell migration. |
| ln Vivo |
In CD-1 mice, tetraconazole nitrate (1% (w/v); administered once to the left ear) can prevent ear edema caused by TPA [2].
In vivo, Sertaconazole Nitrate is effective as a topical treatment for superficial cutaneous and mucosal fungal infections. Its anti-inflammatory activity has been observed in animal models, and its antiproliferative effects have been noted in preclinical cancer studies. |
| Enzyme Assay |
Sertaconazole Nitrate's mechanism is studied using cell-free enzyme assays with fungal microsomal preparations. The inhibition of 14α-demethylase activity is measured by quantifying the accumulation of 14α-methyl sterols or the reduction of ergosterol synthesis. The compound is incubated with the enzyme source and a radiolabeled substrate (e.g., [¹⁴C]-lanosterol), and the reaction products are analyzed by chromatography, typically thin-layer chromatography (TLC) or high-performance liquid chromatography (HPLC).
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Candida albicans, Candida quillimoniensis, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida glabrata Tested Concentrations: 0.03-40 µg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Against 150 strains of yeast (six species of Candida), including Candida albicans, Candida quillimoniensis, Candida krusei, Candida parapsilosis, Candida tropicalis, and Candida glabrata, the arithmetic mean MIC value is 1.02 , 0.51, 0.38, 0.31, 1.67 and 0.78 are micrograms/ml respectively. Western Blot Analysis[2] Cell Types: HaCaT cells Tested Concentrations: 1 µg/mL Incubation Duration: 5, 10, 30, 60 minutes Experimental Results: demonstrated activity to activate p38 MAP kinase and Hsp27 in a time-dependent manner. Western Blot Analysis[2] Cell Types: HaCaT cells Tested Concentrations: 1, 2 µg/mL Incubation Duration: 6 or 8 hrs (hours) Experimental Results: Induced COX-2 expression by 50%, resulting in a twofold increase in PGE2 release. Western Blot Analysis[2] Cell Types: siRNA-transfected HaCaT cells (no p38 MAP kinase expressio Sertaconazole Nitrate's activity against fungal cells is assessed using broth microdilution methods (e.g., CLSI M27-A3 for yeasts or M38-A2 for molds) to determine minimum inhibitory concentrations (MICs). For its anticancer activity, various cancer cell lines (e.g., breast, colon) are used in proliferation assays (e.g., MTT or SRB). Cells are treated with increasing concentrations of the compound for 48-72 hours, and cell viability or apoptosis is measured to determine IC50 values. |
| Animal Protocol |
Animal/Disease Models: CD-1 mice (TPA-induced ear edema model) [2].
Doses: 1% (w/v) Route of Administration: Apply to left ear once. Experimental Results: Dramatically diminished inflammation in mice by mediating PGE2 release. In vivo animal experiments for antifungal efficacy typically involve guinea pig or mouse models of dermatophytosis or cutaneous candidiasis. The compound is applied topically, and infection severity is scored. For anticancer activity, xenograft mouse models are used where tumor-bearing mice are treated with the compound, and tumor volume and weight are measured. |
| ADME/Pharmacokinetics |
Sertaconazole Nitrate is administered topically for its primary antifungal indication. As a topical agent, systemic absorption is minimal, and the drug acts locally at the site of application. PK studies in humans show low plasma concentrations following topical administration, with the drug remaining largely in the stratum corneum.
|
| Toxicity/Toxicokinetics |
Topical Sertaconazole Nitrate is generally well-tolerated with low systemic toxicity due to minimal absorption. Local skin irritation may occur at the application site. In preclinical studies, the compound has shown cytotoxic effects on cancer cells, but with a favorable safety profile for topical use.
|
| References |
|
| Additional Infomation |
Sertaconazole nitrate is the nitrate form of sertaconazole, a synthetic imidazole derivative with antifungal activity. Sertaconazole nitrate inhibits the C-14α-demethylation of fungal cytochrome P-450 sterols, leading to the accumulation of 14α-methylsterol in fungi, and inhibits the synthesis of ergosterol, an important component of the fungal cell membrane. This results in disruption of cell membrane permeability and leakage of adenosine triphosphate (ATP) and other components from the fungal cell.
See also: Sertaconazole (containing the active moiety). Sertaconazole Nitrate is marketed under various brand names including Ertaczo, Dermofix, Konzert, and Zalain for the topical treatment of fungal skin infections. Its unique properties include both antifungal and anti-inflammatory activities, as well as antiproliferative effects on cancer cells. It has received regulatory approval in multiple countries for dermatological use. |
| Molecular Formula |
C20H16CL3N3O4S
|
|---|---|
| Molecular Weight |
500.78
|
| Exact Mass |
498.992
|
| CAS # |
99592-39-9
|
| Related CAS # |
Sertaconazole;99592-32-2
|
| PubChem CID |
200103
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
614.1ºC at 760mmHg
|
| Melting Point |
158-160°
|
| Flash Point |
325.2ºC
|
| LogP |
7.191
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
513
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HAAITRDZHUANGT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H15Cl3N2OS.HNO3/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)222-1(3)4/h1-8,11-12,19H,9-10H2(H,2,3,4)
|
| Chemical Name |
1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazolenitric acid
|
| Synonyms |
Dermofix Ertaczo Zalain Dermoseptic Ginedermofix Mykosert
sertaconazole Zalain
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~199.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9969 mL | 9.9844 mL | 19.9688 mL | |
| 5 mM | 0.3994 mL | 1.9969 mL | 3.9938 mL | |
| 10 mM | 0.1997 mL | 0.9984 mL | 1.9969 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA